Larissa Warneck-Silvestrin

About

Science journalist at Labiotech.eu. Born half Kiwi, half German. I have a BSc in Biology and an MSc in Science Communication from different Universities. I love writing, painting and eating chocolate. Sometimes, I share.

Articles by Larissa Warneck-Silvestrin

Basel, Switzerland, city, biotech ecosystem

Basel: It Takes an Ecosystem to Build a Startup

Europe has a number of bubbling biotech hubs that offer access to expertise, financial support, and networking opportunities for young healthcare ventures. One of them is the Basel Area in Switzerland. It goes without saying that the basis of each biotech should always be world-class innovation. But that is just the beginning: In order to […]

March 7, 2023 - 8 minutesmins - By Larissa Warneck-Silvestrin

Best in Biotech 20 Dec 2021

The Billion-Euro European Biotech Companies in 2022

Here’s a list of the public European biotech companies that are worth more than a billion euros in 2022. European biotech is growing steadily and this year we welcome a few new names to the list of billion-euro biotechs. However, we also had to say goodbye to some of them, including Cellectis, Autolus, and Orchard […]

December 20, 2021 - 12 minutesmins - By Larissa Warneck-Silvestrin

Interview 31 May 2021

What’s Ahead for European Biotech Startups After Covid?

With a tumultuous year behind us, 2021 is set out to spell change for many startups in the European biotech ecosystem. Following the Covid-19 pandemic and Brexit, the European biotech startup landscape has seen some big changes over the course of the past year. Jason Mellad and Dan Rooke, CEO and COO of the Cambridge-based […]

May 31, 2021 - 8 minutesmins - By Larissa Warneck-Silvestrin

Interview 10 May 2021

The Rollercoaster of Repurposing an Arthritis Drug for Covid-19

The Covid-19 pandemic created an opportunity for many biotech companies to repurpose their existing programs into vaccines and treatments for the novel coronavirus. Cyxone’s CEO Tara Heitner and COO Malin Berthold discuss how they approached this shift at their company. Cyxone was founded in 2015 to develop drugs for rheumatoid arthritis and multiple sclerosis. Based […]

May 10, 2021 - 8 minutesmins - By Larissa Warneck-Silvestrin

Interview 5 Apr 2021

Base Editing: The Next Frontier in Genome Editing Technology

Jonathan Frampton, Corporate Development Partner at Horizon Discovery, a Perkin Elmer company, shares his insights into the promises of base editing technology. In less than a decade, the advent of CRISPR-Cas9 has made gene editing easier and faster than ever. But CRISPR, as well as earlier genome editing tools, have a series of technical limitations, […]

April 5, 2021 - 4 minutesmins - By Larissa Warneck-Silvestrin

Interview 15 Mar 2021

Developing a Vaccine that Protects Against Covid-19 Variants

Despite the promise of several approved Covid-19 vaccines and the widespread rollout of vaccination programs around the world, recent mutations in the virus causing Covid-19 are raising concern. Can the current vaccines protect against different coronavirus variants? Paul Higham became CEO of the Finnish firm Valo Therapeutics in 2020. The company was founded in 2016 […]

March 15, 2021 - 8 minutesmins - By Larissa Warneck-Silvestrin

Interview 3 Mar 2021

The Promises of CRISPR Genome Editing in Biomedicine

Tony Ho, Head of Research and Development at CRISPR Therapeutics, offers his insights into the advantages of CRISPR gene editing over other technologies and what the future holds for the genome editing field. For decades, gene editing required engineering DNA-cutting enzymes, such as zinc-finger nucleases (ZFNs) and transcription activator-like effector nucleases (TALENs), for every specific […]

March 3, 2021 - 5 minutesmins - By Larissa Warneck-Silvestrin

Best in Biotech 11 Jan 2021

The 21 European Biotech Companies To Watch in 2021

As we enter 2021, the biotech industry is already bustling with activity. Here’s a list of 21 European biotech companies likely to make a big splash in the biotechnology sector over the next year. There were many memorable moments for the European biotech industry in 2020. The Covid-19 pandemic took over the media and many […]

January 11, 2021 - 11 minutesmins - By Larissa Warneck-Silvestrin

Reports 11 Nov 2020

Navigating the Immunotherapy Maze

Today, the global immunotherapy drugs market is valued at €139B ($163B) and is estimated to reach a staggering value of €149.3B ($174.6B) by 2025. Without a doubt, it is a flourishing field with new research emerging as you read. Discover now how antibodies, T cells, and exosomes are changing the immunotherapy field! While antibodies have […]

November 11, 2020 - 2 minutesmins - By Larissa Warneck-Silvestrin

Interview 28 Oct 2020

Do Natural Killer Cells Hold the Key to Treating Blood Cancers?

Novel immunotherapies, like T cell therapy, may have shown recent successes but they also come with a number of setbacks, such as long timelines and serious adverse reactions. As CEO of the Dutch biotech Kiadis Pharma, Arthur Lahr has been leading the development of a technology that could overcome these limitations by using natural killer […]

October 28, 2020 - 7 minutesmins - By Larissa Warneck-Silvestrin

Interview 5 Oct 2020

How is Germany Meeting Patient Demand for Medical Cannabis?

Since Germany legalized cannabis for medical use in 2017, we have frequently spoken to Peter Homberg, Partner and Head of the German Life Sciences Practice and the European Cannabis Group at Dentons, a global law firm. Over the years, Peter has provided us with regular updates on the European and German medical cannabis industry. In […]

October 5, 2020 - 7 minutesmins - By Larissa Warneck-Silvestrin

Reports 30 Jul 2020

Current and Emerging Therapeutic Approaches for Autoimmune Diseases

Over 4% of the world’s population suffers from one or more of over 80 autoimmune diseases identified to date. A large variety of treatment approaches has already been developed to curb the detrimental effects of autoimmune diseases, and the market continues to flourish. In fact, it is estimated to reach a staggering value of €7.06B […]

July 30, 2020 - 3 minutesmins - By Larissa Warneck-Silvestrin

Resources

Categories

10 biotech companies to watch in 2025

Biotech in 2024: A retrospective

Approaches

Therapeutic areas

Grab your free report on 3D organoids and explore their future potential

Five biosimilar companies you should know about

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

10 biotech companies to watch in 2025

Biotech in 2024: A retrospective

Grab your free report on 3D organoids and explore their future potential

Five biosimilar companies you should know about

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Larissa Warneck-Silvestrin

About

Articles by Larissa Warneck-Silvestrin

Basel: It Takes an Ecosystem to Build a Startup

The Billion-Euro European Biotech Companies in 2022

What’s Ahead for European Biotech Startups After Covid?

The Rollercoaster of Repurposing an Arthritis Drug for Covid-19

Base Editing: The Next Frontier in Genome Editing Technology

Developing a Vaccine that Protects Against Covid-19 Variants

The Promises of CRISPR Genome Editing in Biomedicine

The 21 European Biotech Companies To Watch in 2021

Navigating the Immunotherapy Maze

Do Natural Killer Cells Hold the Key to Treating Blood Cancers?

How is Germany Meeting Patient Demand for Medical Cannabis?

Current and Emerging Therapeutic Approaches for Autoimmune Diseases

Subscribe to our newsletter to get the latest biotech news!

10 biotech companies to watch in 2025

Biotech in 2024: A retrospective

Grab your free report on 3D organoids and explore their future potential

Five biosimilar companies you should know about

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

10 biotech companies to watch in 2025

Biotech in 2024: A retrospective

Grab your free report on 3D organoids and explore their future potential

Five biosimilar companies you should know about

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

About

Articles by Larissa Warneck-Silvestrin

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!